logo

Aldeyra Therapeutics, Inc. (ALDX)



Trade ALDX now with
  Date
  Headline
5/18/2022 8:13:17 AM ALDX : Phase 3 Trial Shows Significance In Favor Of Reproxalap Over Vehicle For Primary Endpoint Of Ocular Redness
4/5/2022 8:04:23 AM Aldeyra Therapeutics Completes Enrollment In Phase 3 TRANQUILITY-2 Trial In Patients With Dry Eye Disease
3/17/2022 7:08:59 AM Aldeyra Therapeutics FY Net Loss $57.8 Mln Vs. Net Loss $37.6 Mln Last Year
3/8/2022 8:05:53 AM Aldeyra Therapeutics Begins Phase 2 Trial Of ADX-2191 For Treatment Of Retinitis Pigmentosa
2/1/2022 8:08:32 AM Aldeyra Therapeutics Announces Publication Of Phase 2 Clinical Trial Of Reproxalap In Allergen Chamber Model
1/11/2022 8:10:56 AM Aldeyra Announces Positive Data From Phase 2 Dry Eye Chamber Trial Of Reproxalap Vs. Xiidra
1/4/2022 8:10:13 AM Aldeyra Completes Enrollment In Part 1 Of Phase 3 Trial of ADX-2191 In Proliferative Vitreoretinopathy
11/9/2021 8:14:42 AM Aldeyra Therapeutics Completes Enrollment In Phase 3 TRANQUILITY Trial In Patients With Dry Eye Disease
11/2/2021 8:28:41 AM Aldeyra Therapeutics Achieves Primary Endpoint Of Ocular Redness In Phase 2 Clinical Trial In Dry Eye Disease
10/28/2021 7:41:03 AM Aldeyra Therapeutics Q3 Net Loss $15.8 Mln Vs Net Loss $8.9 Mln Last Year
8/5/2021 7:19:22 AM Aldeyra Therapeutics Q2 Net Loss $14.9 Mln Vs Net Loss $7.5 Mln Last Year
8/4/2021 8:07:51 AM Aldeyra Receives Orphan Drug Designation From FDA For ADX-2191 To Treat Retinitis Pigmentosa
7/20/2021 8:04:52 AM Aldeyra Therapeutics Says Gets Orphan Drug Designation From US FDA For ADX-2191 To Treat Primary Vitreoretinal Lymphoma
4/27/2021 7:55:51 AM Aldeyra Achieves Primary Endpoint And All Secondary Endpoints In Phase 3 Trial Of Reproxalap In Allergic Conjunctivitis
3/11/2021 7:12:40 AM Aldeyra Therapeutics Net Loss For Full-year 2020 $37.6 Mln Or $1.11 Per Share